143 related articles for article (PubMed ID: 33193845)
1. EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma.
Taher MM; Dairi G; Butt EM; Al-Quthami K; Al-Khalidi H; Jastania RA; Nageeti TH; Bogari NM; Athar M; Al-Allaf FA; Valerie K
Oncol Lett; 2020 Dec; 20(6):384. PubMed ID: 33193845
[TBL] [Abstract][Full Text] [Related]
2. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
Loussouarn D; Le Loupp AG; Frenel JS; Leclair F; Von Deimling A; Aumont M; Martin S; Campone M; Denis MG
Int J Oncol; 2012 Jun; 40(6):2058-62. PubMed ID: 22447191
[TBL] [Abstract][Full Text] [Related]
3. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J
Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305
[TBL] [Abstract][Full Text] [Related]
6. Mutation profiling of anaplastic ependymoma grade III by Ion Proton next generation DNA sequencing.
Butt E; Alyami S; Nageeti T; Saeed M; AlQuthami K; Bouazzaoui A; Athar M; Abduljaleel Z; Al-Allaf F; Taher M
F1000Res; 2019; 8():613. PubMed ID: 32612806
[No Abstract] [Full Text] [Related]
7. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
[TBL] [Abstract][Full Text] [Related]
8. Adamantinomatous Craniopharyngioma in an Adult: A Case Report with NGS Analysis.
Jastania RA; Saeed M; Al-Khalidi H; AlQuthami K; Nageeti TH; Al-Allaf FA; Valerie K; Taher MM
Int Med Case Rep J; 2020; 13():123-137. PubMed ID: 32368160
[TBL] [Abstract][Full Text] [Related]
9. A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas.
Pang B; Durso MB; Hamilton RL; Nikiforova MN
Diagn Mol Pathol; 2013 Mar; 22(1):28-34. PubMed ID: 23370430
[TBL] [Abstract][Full Text] [Related]
10. Implications of Concurrent
Yuile A; Satgunaseelan L; Wei J; Kastelan M; Back MF; Lee M; Wei H; Buckland ME; Lee A; Wheeler HR
Curr Issues Mol Biol; 2022 Oct; 44(10):5117-5125. PubMed ID: 36286062
[TBL] [Abstract][Full Text] [Related]
11. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
12. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1
Acquaviva G; Visani M; de Biase D; Marucci G; Franceschi E; Tosoni A; Brandes AA; Rhoden KJ; Pession A; Tallini G
Sci Rep; 2018 Mar; 8(1):4459. PubMed ID: 29535392
[TBL] [Abstract][Full Text] [Related]
14. Mutation Profiling of Intracranial Myxopapillary Ependymoma by Next Generation DNA Sequencing.
Taher MM; Alhussini AA; Saeed M; Athar M; Bantan NAA; Jastania RA; Balkhoyour KB; Nageeti TH
Gulf J Oncolog; 2021 Sep; 1(37):7-16. PubMed ID: 35152189
[TBL] [Abstract][Full Text] [Related]
15. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
16. Supratentorial Sporadic Hemangioblastoma: A Case Report With Mutation Profiling Using Next-Generation DNA Sequencing.
Taher MM; Bantan NA; Alwalily MH; Saeed M; Taher NM; Bouzidi M; Jastania RA; Balkhoyour KB
Cureus; 2023 Jun; 15(6):e39818. PubMed ID: 37273678
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
18. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
20. Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma.
Xu S; Cao L; Chen R; Ye C; Li Q; Jiang Q; Yan F; Wan M; Zhang X; Ruan J
Oncologist; 2024 Jun; ():. PubMed ID: 38842680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
